Ginkgo Bioworks Q3 revenue falls 6% to $27.7M
The quarter paired a 6% year-over-year revenue decline with lower reported losses and a $285 million cash-and-securities balance.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
8-K
Rhea-AI Filing Summary
Ginkgo Bioworks Holdings, Inc. reported third-quarter 2026 revenue of $27.711 million, down 6% from $29.380 million a year earlier and up from $20 million in Q2. Its GAAP net loss from continuing operations was $40.984 million, compared with $73.354 million; Adjusted EBITDA was ($22) million, versus ($53) million. Cash, cash equivalents and marketable securities totaled $285 million as of September 30, 2026, and quarterly cash burn was $27 million. Ginkgo reaffirmed expected 2026 total cash burn of ($150)-($125) million.
Ginkgo described autonomous lab equipment and Cloud Lab services as its two offerings. It announced a sale of an autonomous lab to Novo at its new Waltham, Massachusetts R&D site, plus an ARPA-H GIVE subcontract worth up to $17.5 million for RAC and Catalyst systems in RNA-medicine manufacturing. In Q3, 22 ADME customers signed, including 20 first-time Ginkgo customers; GSK, Novartis and Biogen also signed new work, and OpenAI is using Cloud Lab for AI data generation.
2 points · 0 major0 major · 1 point
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Positive
- Moderate pointContinuing-operations net loss declined to $40.984 million from $73.354 million.
- Moderate pointAdjusted EBITDA loss improved to ($22) million from ($53) million.
Negative
- Moderate pointRevenue declined 6% year over year to $27.711 million.
Filing Explained
The accompanying cash-flow statement records ATM-offering proceeds and related issuance costs for the nine months ended
8-K Event Classification
2 items: 2.02, 9.01
2 items
Item 2.02
Results of Operations and Financial Condition
Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
Revenue: $27.711 million
GAAP net loss from continuing operations: $40.984 million loss
Adjusted EBITDA: ($22) million
+4 more
7 metrics
Revenue
$27.711 million
Third quarter 2026; $29.380 million in the comparable 2025 quarter
GAAP net loss from continuing operations
$40.984 million loss
Third quarter 2026; $73.354 million loss in the comparable 2025 quarter
Adjusted EBITDA
($22) million
Third quarter 2026; ($53) million in the comparable 2025 quarter
Cash, cash equivalents and marketable securities
$285 million
As of September 30, 2026
Cash burn
$27 million
Third quarter 2026
Expected total cash burn
($150)-($125) million
2026 outlook
ARPA-H GIVE subcontract
Up to $17.5 million
For RAC and Catalyst systems in RNA-medicine manufacturing
Key Terms
Adjusted EBITDA, ADME, RACs, Cloud Lab, +1 more
5 terms
Adjusted EBITDA financial
"Third quarter 2026 Adjusted EBITDA of ($22) million"
Adjusted EBITDA is a way companies measure how much money they make from their core operations, like running a business, by removing certain costs or income that aren’t part of regular business activities. It helps investors see how well a company is doing without distractions from unusual expenses or gains, making it easier to compare companies or track performance over time.
ADME technical
"delivering onshore ADME, DRUG-seq and antibody data"
ADME stands for Absorption, Distribution, Metabolism and Excretion — the four processes that determine how a drug enters the body, moves to target tissues, is chemically changed, and is removed. For investors, ADME profiles signal whether a drug is likely to be effective, safe and practical to dose; weak ADME can sink a program just like delivery problems can ruin a product launch, while strong ADME improves chances of regulatory approval and commercial success.
RACs technical
"more than 100 reconfigurable automation carts (RACs)"
Cloud Lab technical
"Cloud Lab Services"
A cloud lab is a remotely operated laboratory where automated instruments and robotic systems run experiments on behalf of users who send protocols over the internet. For investors it matters because companies can outsource costly equipment and staff, scale research faster, and reduce the risk that a single lab breakdown will stall product development—similar to renting a shared, online factory instead of building your own.
cash burn financial
"expected total cash burn of ($150)-($125) million in 2026"
Cash burn is the speed at which a company uses its available cash to pay for day‑to‑day operations, development and other outflows, usually expressed over a month or year. Investors care because it acts like a car’s fuel gauge: a high burn rate relative to cash on hand means the business may soon need extra financing or cut spending, while a low burn rate suggests greater financial stability and more time to grow.
Earnings Snapshot
Revenue: $27.711 million · Guidance included
Third quarter 2026
Revenue
$27.711 million
Down 6% from $29.380 million in Q3 2025; increased from $20 million in Q2 2026
GAAP net loss from continuing operations
$40.984 million loss
Compared with $73.354 million loss in Q3 2025
Adjusted EBITDA
($22) million
Improved from ($53) million in Q3 2025
Guidance
Ginkgo reaffirmed expected total cash burn of ($150)-($125) million in 2026.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What were Ginkgo's Q3 2026 revenue and losses?
Ginkgo reported revenue of $27.711 million, down 6% from $29.380 million in Q3 2025. GAAP net loss from continuing operations was $40.984 million, compared with $73.354 million, and Adjusted EBITDA was ($22) million versus ($53) million.
How much is the ARPA-H GIVE subcontract?
Ginkgo reported an ARPA-H GIVE subcontract worth up to $17.5 million. The work is to put RACs and Catalyst into RNA-medicine manufacturing for the first time.
How many ADME customers signed with Ginkgo in Q3 2026?
Ginkgo said 22 ADME customers signed in Q3, and 20 were first-time Ginkgo customers.
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
______________________________________________________________
FORM 8-K
______________________________________________________________
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): November 5, 2026
______________________________________________________________
(Exact name of registrant as specified in its charter)
______________________________________________________________
| (State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||||||||||||
(Address of principal executive offices, including zip code)
Registrant’s telephone number, including area code: (877 ) 422-5362
(Former name or former address, if changed since last report)
______________________________________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||||
Securities registered pursuant to Section 12(b) of the Act
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 2.02. Results of Operations and Financial Condition.
On November 5, 2026, Ginkgo Bioworks Holdings, Inc. issued a press release announcing its financial results for the third quarter ended September 30, 2026. A copy of the press release is furnished with this Current Report on Form 8-K as Exhibit 99.1.
Ginkgo announces material information to the public through a variety of means, including filings with the SEC, public conference calls, its website (https://www.ginkgo.bio), its investor relations website (https://investors.ginkgobioworks.com) and its news site (https://investors.ginkgobioworks.com/news). Ginkgo uses these channels, as well as its blog (https://www.ginkgo.bio/resources) and social media accounts on X (@Ginkgo), Instagram (@GinkgoBioworks), Threads (@GinkgoBioworks) and LinkedIn to communicate with investors and the public about the Company and other matters and encourages investors, the media, and others interested in the Company to review the information it makes public in these locations, as such information could be deemed to be material information.
Item 9.01. Financial Statements and Exhibits.
(d)Exhibits.
| Exhibit Number | Description | |||||||
| 99.1 | Press Release, issued by Ginkgo Bioworks Holdings, Inc. on November 5, 2026 | |||||||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL) | |||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| GINKGO BIOWORKS HOLDINGS, INC. | ||||||||
| Date: November 5, 2026 | By: | /s/ Steven Coen | ||||||
| Name: | Steven Coen | |||||||
| Title: | Chief Financial Officer | |||||||
Exhibit 99.1
Ginkgo Bioworks Reports Third Quarter 2026 Results; Signs First Autonomous Lab Sale to a Top-Tier Pharma Company Novo
Ginkgo provides an update on its third quarter financial results and the growth of its two prevailing offerings built on one autonomous lab platform: Autonomous Labs and Cloud Lab
BOSTON, Mass – November 5, 2026 – Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, “Ginkgo”) today announced its results for the third quarter of 2026 that ended September 30, 2026. The update, including a webcast slide presentation with additional details on the third quarter, as well as supplemental financial information, will be available at investors.ginkgobioworks.com.
Third Quarter 2026 Financial Results
•Third quarter 2026 Revenue of $28 million compared to $29 million in the comparable prior year period, a decrease of 6%. Revenue increased from $20 million in the second quarter of 2026.
•Third quarter 2026 GAAP net loss from continuing operations of ($41) million, compared to ($73) million in the comparable prior year period.
•Third quarter 2026 Adjusted EBITDA of ($22) million, improved from ($53) million in the comparable prior year period.
•Cash, cash equivalents and marketable securities balance as of September 30, 2026 of $285 million.
•Third quarter 2026 cash burn of $27 million.
"Ginkgo now has two core offerings built on one autonomous lab platform," said Jason Kelly, Co-founder and CEO of Ginkgo Bioworks. "This quarter we announced the sale of an autonomous lab to a top-tier pharma company, Novo, alongside new government wins with ARPA-H and the NSF. Our Cloud Lab runs experiments on Nebula, the world's largest autonomous lab, giving pharma an onshore alternative to overseas CROs and giving frontier AI labs a new engine for training data. With the U.S. government now treating autonomous labs as national infrastructure, we believe Ginkgo is well positioned to lead the transition from the bench to autonomous research."
Recent Business Highlights & Strategic Positioning
•Two prevailing offerings built on one autonomous lab platform.
◦Autonomous Labs Equipment: we sell RAC + Catalyst systems to pharma, national labs, universities and the U.S. government, including Novo, Pacific Northwest National Laboratory, the NSF and ARPA-H.
◦Cloud Lab Services: we run experiments in Nebula, the world’s largest autonomous lab with more than 100 reconfigurable automation carts (RACs), delivering onshore ADME, DRUG-seq and antibody data for pharma, and AI training data for frontier labs and techbio companies.
◦The U.S. government is making autonomous labs national infrastructure through the Genesis Mission, the NSF’s ~$400 million Programmable Cloud Laboratories (PCL) Test Bed, and the $1.5 billion X-Labs initiative, where Ginkgo is providing access to Nebula, as announced by the White House Office of Science and Technology Policy on October 8.
•Autonomous Labs are growing with new deals.
◦Novo: an autonomous lab sale to a top-tier pharma company at Novo’s new Waltham, Massachusetts R&D site.
◦ARPA-H GIVE: subcontract worth up to $17.5 million to put RACs and Catalyst into RNA-medicine manufacturing for the first time.
◦Building on momentum from previously-announced Caltech, University of Maryland and Northwestern commissions of Ginkgo-built labs under the NSF’s PCL Test Bed, and MIT Media Lab’s construction of a RAC-based cloud lab.
•Cloud Lab is growing with new pharma logos and AI data generation.
◦Our ADME-One service is orders of magnitude cheaper than WuXi, with work done in Boston; 22 ADME customers signed in Q3 and 20 were first-time Ginkgo customers.
◦Takeda, Argenx, Lundbeck and AbbVie founded our Antibody Developability Consortium; GSK, Novartis and Biogen also signed new work.
◦Frontier AI labs like OpenAI are using our Cloud Lab for AI data generation.
Full Year 2026 Outlook
•Ginkgo reaffirms expected total cash burn of ($150)-($125) million in 2026.
Conference Call Details
Ginkgo will host a videoconference today, Thursday, November 5, beginning at 4:30 p.m. ET. The presentation will include an overview of the third quarter 2026, recent business updates, a discussion on Ginkgo’s outlook, as well as a moderated question and answer session.
To ask a question ahead of the presentation, please submit your questions to @Ginkgo on X (hashtag #GinkgoResults) or by sending an e-mail to investors@ginkgobioworks.com.
A webcast link is available on Ginkgo's Investor Relations website and a replay will be made available following the presentation.
Ginkgo Investor Website: https://investors.ginkgobioworks.com/events/
Audio-Only Dial Ins:
+1 646 876 9923 (New York - ET)
+1 301 715 8592 (Washington DC - ET)
+1 305 224 1968 (Miami - ET)
+1 689 278 1000 (Orlando - ET)
+1 312 626 6799 (Chicago - CT)
+1 507 473 4847 (Minnesota - CT)
+1 346 248 7799 (Houston - CT)
+1 719 359 4580 (Colorado - MT)
+1 408 638 0968 (San Jose - PT)
Webinar ID: 952 0773 4867
If you experience technical difficulties with any of these dial-ins or if you need international dial-in numbers, please visit our website at https://investors.ginkgobioworks.com/events/ for updated dial-in information.
About Ginkgo Bioworks
Ginkgo Bioworks builds the tools that make biology easier to engineer for everyone. The company offers autonomous laboratories that replace manual laboratory work with robotics in the lab, greatly improving the productivity of scientists. Ginkgo's in-house autonomous lab is also available as a "Cloud Lab" through our Datapoints and Solutions contract research services. For more information, visit ginkgobioworks.com, read our blog, or follow us on social media channels such as X (@Ginkgo), Instagram (@GinkgoBioworks), Threads (@GinkgoBioworks), or LinkedIn.
Forward-Looking Statements of Ginkgo Bioworks
This press release, the presentation, and the conference call and webcast contain certain forward-looking statements within the meaning of the federal securities laws, including statements regarding our plans, including with respect to technology adaptations to meet our customers’ needs and the integration of our autonomous lab platform with third-party artificial intelligence models, strategies, including with respect to our current expectations, operations and anticipated results of operations, both business and financial, potential customer success, including successful application of our offerings by our customers, expected benefits from our strategic partnerships and collaborations (including with named partners such as Novo and OpenAI), the anticipated growth, scaling, capacity, capabilities and competitive position of our
autonomous lab (including Nebula) and of our Cloud Lab, Datapoints and Solutions offerings, our beliefs and estimates regarding the size, composition, growth and pace of adoption of the market for autonomous laboratory and related services (including the displacement of manual laboratory work), expectations concerning increased government investment in and contracting for autonomous laboratory infrastructure, expectations regarding the development, performance and future enhancements of our platform and new product and service introductions, and expectations with regard to revenue, including our ability to meet all milestones and achieve the maximum revenue available under certain of our customer arrangements, expenses, our full year 2026 outlook including the total cash burn guidance, and the market environment, all of which are subject to known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements, market trends, or industry results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements generally are identified by the words "believe," "can," "project," "potential," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," "target," "goal," "aim," "design," "forecast," "outlook," "guidance," "seek" "position," and similar expressions, as well as the negatives of such terms. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this document, including but not limited to: (i) our ability to realize near-term and long-term cost savings associated with our site consolidation plans, including the ability to terminate leases or find sub-lease tenants for unused facilities, (ii) volatility in the price of Ginkgo's securities due to a variety of factors, including changes in the competitive and highly regulated industries in which Ginkgo operates and plans to operate, variations in performance across competitors, and changes in laws and regulations affecting Ginkgo's business, (iii) the ability to implement business plans, forecasts, and other expectations, and to identify and realize additional business opportunities, including with respect to our solutions and tools offerings, (iv) the risk of downturns in demand for products using synthetic biology, (v) the uncertainty regarding the demand for passive monitoring programs and biosecurity services, (vi) changes to the biosecurity industry, including due to advancements in technology, emerging competition and evolution in industry demands, standards and regulations, (vii) the outcome of any pending or potential legal proceedings against Ginkgo, (viii) our ability to realize the expected benefits from and the success of our platform programs and assets, (ix) our ability to successfully develop engineered cells, bioprocesses, data packages or other deliverables, (x) the product development, production or manufacturing success of our customers, (xi) our exposure to the volatility and liquidity risks inherent in holding equity interests in other operating companies and other non-cash consideration we may receive for our services, (xii) the potential negative impact on our business of our restructuring or the failure to realize the anticipated savings associated therewith, (xiii) the uncertainty regarding government budgetary priorities and funding allocated to government agencies, including potential adverse effects from the U.S. government shutdown, (xiv) our ability to scale, expand the capacity of, and continue to develop the capabilities of our autonomous lab (including Nebula) on the timelines and to the extent we anticipate, (xv) the pace and degree to which autonomous laboratory infrastructure is adopted by, and displaces manual laboratory work in, the broader life sciences and industrial biotechnology markets, (xvi) the actual size, composition and growth of the addressable markets we target, which may differ materially from our estimates, (xvii) our ability to integrate our autonomous lab platform with third-party artificial intelligence models and other technologies, and the rate of development and adoption of such technologies, (xviii) our ability to maintain and expand strategic partnerships and customer relationships, including those with named partners referenced in this release, and (xix) the risks relating to significant disruptions to our and our service providers’ information technology systems or data security incidents. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the "Risk Factors" section of Ginkgo's annual report on Form 10-K filed with the U.S. Securities and Exchange Commission (the "SEC") on February 26, 2026, Ginkgo’s quarterly report on Form 10-Q, once filed, and other documents filed by Ginkgo from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Ginkgo assumes no obligation to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Ginkgo does not give any assurance that it will achieve its expectations.
Use of Non-GAAP Financial Measures
Certain of the financial measures included in this release, including Adjusted EBITDA, cash flow and cash burn, have not been prepared in accordance with generally accepted accounting principles ("GAAP"), and constitute "non-GAAP financial measures" as defined by the SEC. Ginkgo has included these non-GAAP financial measures because it believes they provide an additional tool for investors to use in evaluating Ginkgo's financial performance and prospects. Due to the nature and/or size of the items being excluded, such items do not reflect future gains, losses, expenses or benefits and are not indicative of our future operating performance. These non-GAAP financial measures are supplemental to, and should not be considered in isolation from, or as an alternative to, financial measures determined in accordance with
GAAP. In addition, these non-GAAP financial measures may differ from non-GAAP financial measures with comparable names used by other companies. See the reconciliation in the Appendix of this quarter’s earnings presentation for additional information regarding certain of the non-GAAP financial measures included in this release, including a description of these non-GAAP financial measures and a reconciliation of the historic measures to Ginkgo's most comparable GAAP financial measures. Ginkgo does not reconcile its forward-looking non-GAAP financial measures to the corresponding GAAP measures, due to variability and difficulty in making accurate forecasts and projections and/or certain information not being ascertainable or accessible; and because not all of the information, such as unrealized equity gains and losses necessary for a quantitative reconciliation of these forward-looking non-GAAP financial measures to the most directly comparable GAAP financial measure, can be predicted with reasonable accuracy and is available to Ginkgo without unreasonable efforts. For the same reasons, Ginkgo is unable to address the probable significance of the unavailable information. Ginkgo provides non-GAAP financial measures that it believes will be achieved, however it cannot accurately predict all of the components of the adjusted calculations and the GAAP measures may be materially different than the non-GAAP measures.
Ginkgo Bioworks Contacts:
INVESTOR CONTACT:
investors@ginkgobioworks.com
MEDIA CONTACT:
press@ginkgobioworks.com
Ginkgo Bioworks Holdings, Inc.
Condensed Consolidated Balance Sheets
(unaudited)
(in thousands, except share data)
| As of September 30, 2026 | As of December 31, 2025 | ||||||||||
Assets | |||||||||||
Current assets: | |||||||||||
Cash and cash equivalents | $ 84,504 | $ 167,202 | |||||||||
Marketable securities | 200,857 | 255,418 | |||||||||
Accounts receivable, net | 11,485 | 24,026 | |||||||||
Accounts receivable - related parties | — | 229 | |||||||||
Prepaid expenses and other current assets (includes $4,208 and zero from related parties) | 13,995 | 24,963 | |||||||||
Total current assets | 310,841 | 471,838 | |||||||||
Restricted cash and marketable securities, non-current | 84,237 | 38,138 | |||||||||
Property, plant and equipment, net | 152,347 | 167,371 | |||||||||
Operating lease right-of-use assets | 341,494 | 360,918 | |||||||||
Investments | 8,949 | 15,066 | |||||||||
Equity method investments | 5,607 | — | |||||||||
Intangible assets, net | 39,731 | 53,482 | |||||||||
Other non-current assets | 1,246 | 9,029 | |||||||||
Assets held for sale | — | 3,854 | |||||||||
Total assets | $ 944,452 | $ 1,119,696 | |||||||||
Liabilities and Stockholders’ Equity | |||||||||||
Current liabilities: | |||||||||||
Accounts payable | $ 7,181 | $ 10,566 | |||||||||
Deferred revenue (includes $98 and $98 from related parties) | 6,388 | 18,946 | |||||||||
Accrued expenses and other current liabilities (includes $5,564 and zero from related parties) | 52,280 | 66,458 | |||||||||
Total current liabilities | 65,849 | 95,970 | |||||||||
Non-current liabilities: | |||||||||||
Deferred revenue, net of current portion (includes $64,810 and $64,787 from related parties) | 71,977 | 75,182 | |||||||||
Operating lease liabilities, non-current | 397,198 | 417,078 | |||||||||
Other non-current liabilities | 16,791 | 22,876 | |||||||||
Total liabilities | 551,815 | 611,106 | |||||||||
Commitments and contingencies (Note 10) | |||||||||||
Stockholders’ equity: | |||||||||||
Preferred stock, $0.0001 par value; 200,000,000 shares authorized; none issued | — | — | |||||||||
| Common stock, $0.0001 par value (Note 8) | 6 | 6 | |||||||||
Additional paid-in capital | 6,713,117 | 6,657,053 | |||||||||
Accumulated deficit | (6,320,601) | (6,150,320) | |||||||||
Accumulated other comprehensive income | 115 | 1,851 | |||||||||
Total stockholders’ equity | 392,637 | 508,590 | |||||||||
Total liabilities and stockholders’ equity | $ 944,452 | $ 1,119,696 | |||||||||
5
Ginkgo Bioworks Holdings, Inc.
Condensed Consolidated Statements of Operations and Comprehensive Loss
(unaudited)
(in thousands, except share data)
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||
2026 | 2025 | 2026 | 2025 | ||||||||||||||||||||
Revenue (1) | $ 27,711 | $ 29,380 | $ 67,341 | $ 106,744 | |||||||||||||||||||
Costs and operating expenses: | |||||||||||||||||||||||
Cost of other revenue | 1,806 | 4,625 | 6,623 | 14,095 | |||||||||||||||||||
Research and development | 40,945 | 69,353 | 137,075 | 193,646 | |||||||||||||||||||
General and administrative | 28,593 | 36,986 | 97,198 | 111,690 | |||||||||||||||||||
Restructuring charges | — | 721 | — | 8,753 | |||||||||||||||||||
Total operating expenses | 71,344 | 111,685 | 240,896 | 328,184 | |||||||||||||||||||
Loss from operations | (43,633) | (82,305) | (173,555) | (221,440) | |||||||||||||||||||
Other income (expense): | |||||||||||||||||||||||
Interest income, net | 3,060 | 5,742 | 9,888 | 17,906 | |||||||||||||||||||
Loss on equity method investment | (2,008) | — | (6,681) | — | |||||||||||||||||||
Gain (loss) on investments | (287) | 3,684 | 486 | (238) | |||||||||||||||||||
Other income (expense), net | 1,613 | (474) | (4,725) | (6,280) | |||||||||||||||||||
Total other income (expense) | 2,378 | 8,952 | (1,032) | 11,388 | |||||||||||||||||||
Loss from continuing operations before income taxes | (41,255) | (73,353) | (174,587) | (210,052) | |||||||||||||||||||
Income tax (benefit) expense | (271) | 1 | (223) | (194) | |||||||||||||||||||
Net loss from continuing operations | $ (40,984) | $ (73,354) | $ (174,364) | $ (209,858) | |||||||||||||||||||
Net income (loss) from discontinued operations, net of tax | — | (7,401) | 4,083 | (22,154) | |||||||||||||||||||
Net loss | $ (40,984) | $ (80,755) | $ (170,281) | $ (232,012) | |||||||||||||||||||
Net income (loss) per share: | |||||||||||||||||||||||
From continuing operations | $ (0.64) | $ (1.32) | $ (2.82) | $ (3.82) | |||||||||||||||||||
From discontinued operations | — | (0.13) | 0.07 | (0.40) | |||||||||||||||||||
Total net loss per share | $ (0.64) | $ (1.45) | $ (2.75) | $ (4.22) | |||||||||||||||||||
Weighted average common shares outstanding: | 63,966,054 | 55,633,718 | 61,890,748 | 54,916,539 | |||||||||||||||||||
Comprehensive loss: | |||||||||||||||||||||||
Net loss | (40,984) | (80,755) | (170,281) | (232,012) | |||||||||||||||||||
Other comprehensive (loss) income: | |||||||||||||||||||||||
Foreign currency translation adjustment | (515) | 27 | (1,128) | 3,462 | |||||||||||||||||||
Unrealized (loss) gain on available-for-sale securities | (320) | 316 | (608) | 340 | |||||||||||||||||||
Total other comprehensive (loss) income | (835) | 343 | (1,736) | 3,802 | |||||||||||||||||||
Comprehensive loss | $ (41,819) | $ (80,412) | $ (172,017) | $ (228,210) | |||||||||||||||||||
6
(1)Includes related party revenue of zero for the three months ended September 30, 2026 and 2025, and zero and $8,518 for the nine months ended September 30, 2026 and 2025, respectively.
Ginkgo Bioworks Holdings, Inc.
Condensed Consolidated Statements of Cash Flows
(unaudited)
(in thousands)
| Nine Months Ended September 30, | |||||||||||
2026 | 2025 | ||||||||||
Cash flows from operating activities: | |||||||||||
Net loss | $ (170,281) | $ (232,012) | |||||||||
Net income (loss) from discontinued operations, net of tax | 4,083 | (22,154) | |||||||||
Net loss from continuing operations | (174,364) | (209,858) | |||||||||
Adjustments to reconcile net loss to net cash used in operating activities: | |||||||||||
Depreciation and amortization | 37,152 | 43,695 | |||||||||
Stock-based compensation | 31,117 | 51,226 | |||||||||
(Gain) loss on investments | (486) | 275 | |||||||||
Loss on equity method investment | 6,681 | — | |||||||||
Change in fair value of notes receivable | 6,759 | 5,685 | |||||||||
Change in fair value of contingent consideration | — | (4,232) | |||||||||
Non-cash lease expense | 19,423 | 22,449 | |||||||||
Accretion of discount on marketable securities | 89 | (2,502) | |||||||||
Other non-cash activity | (1,057) | 1,611 | |||||||||
Changes in operating assets and liabilities: | |||||||||||
Accounts receivable | 4,968 | 1,448 | |||||||||
Prepaid expenses and other current assets | 3,211 | (775) | |||||||||
Operating lease right-of-use assets | — | 3,814 | |||||||||
Other non-current assets | 297 | (38) | |||||||||
Accounts payable, accrued expenses and other current liabilities | (14,312) | 17,432 | |||||||||
Deferred revenue, current and non-current zero and $(7,958) from related parties | (14,443) | (27,448) | |||||||||
Operating lease liabilities, current and non-current | (16,713) | (18,793) | |||||||||
Other non-current liabilities | (5,276) | 4,459 | |||||||||
Net cash used in operating activities - continuing operations | (116,954) | (111,552) | |||||||||
Net cash used in operating activities - discontinued operations | (2,353) | (11,829) | |||||||||
Net cash used in operating activities | (119,307) | (123,381) | |||||||||
Cash flows from investing activities: | |||||||||||
Purchases of marketable debt securities | (216,800) | (401,838) | |||||||||
Maturities of marketable debt securities | 231,108 | 73,599 | |||||||||
Purchases of property and equipment | (6,552) | (7,660) | |||||||||
7
Proceeds from sale of investment | 1,850 | — | |||||||||
Other | 512 | 511 | |||||||||
Net cash provided by (used in) investing activities | 10,118 | (335,388) | |||||||||
Cash flows from financing activities: | |||||||||||
Proceeds from ATM offering | 23,795 | 10,317 | |||||||||
Payment of issuance costs related to ATM offering | (802) | (355) | |||||||||
Principal payments on finance leases | (19) | (329) | |||||||||
Net cash provided by financing activities | 22,974 | 9,633 | |||||||||
Effect of foreign exchange rates on cash and cash equivalents | (80) | 353 | |||||||||
Net decrease in cash, cash equivalents and restricted cash | (86,295) | (448,783) | |||||||||
Cash and cash equivalents, beginning of period | 167,202 | 561,572 | |||||||||
Restricted cash, beginning of period | 45,169 | 44,171 | |||||||||
Cash, cash equivalents and restricted cash, beginning of period | 212,371 | 605,743 | |||||||||
Cash and cash equivalents, end of period | 84,504 | 111,065 | |||||||||
Restricted cash, end of period | 41,572 | 45,895 | |||||||||
Cash, cash equivalents and restricted cash, end of period | $ 126,076 | $ 156,960 | |||||||||
8
The following table presents summary results of the Company’s reportable segment, including significant expenses, and a reconciliation to loss from continuing operations before income taxes (in thousands):
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||||||
| Cell Engineering | ||||||||||||||||||||
| Revenue | $ 27,711 | $ 29,380 | $ 67,341 | $ 106,744 | ||||||||||||||||
| Costs and operating expenses: | ||||||||||||||||||||
Cost of other revenue (1) | 1,608 | 2,994 | 5,752 | 9,980 | ||||||||||||||||
Research and development (1) | 26,670 | 50,954 | 87,208 | 130,689 | ||||||||||||||||
General and administrative (1) | 9,317 | 13,758 | 33,148 | 49,397 | ||||||||||||||||
Stock-based compensation (2) | 7,767 | 15,249 | 32,512 | 51,732 | ||||||||||||||||
| Depreciation and amortization | 12,038 | 13,624 | 37,152 | 43,695 | ||||||||||||||||
Restructuring charges (3) | — | 721 | — | 8,753 | ||||||||||||||||
Carrying cost of excess space (net of sublease income) (4) | 13,989 | 14,328 | 44,063 | 38,416 | ||||||||||||||||
Merger, acquisition and divestiture related expense (income) (5) | (45) | 57 | 1,061 | (4,478) | ||||||||||||||||
Other (income) expense, net (6) | (2,378) | (8,952) | 1,032 | (11,388) | ||||||||||||||||
| Loss from continuing operations before income taxes | $ (41,255) | $ (73,353) | $ (174,587) | $ (210,052) | ||||||||||||||||
(1) The costs and operating expenses exclude expenses which are separately captioned below.
(2) Includes $0.1 million and $0.2 million in employer payroll taxes for three months ended September 30, 2026 and 2025, respectively, and $1.4 million and $0.7 million for nine months ended September 30, 2026 and 2025, respectively.
(3) See Note 3, Restructuring, for composition of costs.
(4) The carrying cost of excess space includes base rent, common area maintenance charges, and real estate taxes associated with facilities the Company is not occupying, net of any sublease income from these spaces.
(5) Represents transaction and integration costs directly related to mergers, acquisitions, and divestitures, including: (i) legal, consulting, and accounting fees associated with acquisitions; (ii) post-acquisition employee retention bonuses; (iii) (gain)/loss from changes in the fair value of contingent consideration liabilities resulting from acquisitions; and (iv) securities litigation costs.
(6) Includes interest income, interest expense, gain and loss on investments, changes in fair value of certain assets and liabilities, and other gains and losses.
9